Phaseline

Companies › InxMed (Shanghai)

InxMed (Shanghai): clinical trials, targets and expected readouts

4 active drug programs in 16 registered trials: 10 Phase 1, 4 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ifebemtinib (IN10018)
Focal adhesion kinase 1 inhibitor
PTK2Phase 3Non-Small Cell Lung Cancer; Ovarian Cancer Recurrent; Small Cell Lung Cancer Extensive Stage; Pancreatic Cancer …Dec 2026
D-1553
KRAS G12C inhibitor
KRASPhase 3Non-Small Cell Lung Cancer; Solid TumorDec 2027
RNK08954
unclear mechanism
–Phase 1Solid Tumor CancerFeb 2031
Erfonrilimab (KN046)
Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor
CTLA4, CD274Phase 1Pancreatic Cancer; Digestive System Cancers; HER2-positive Locally Advanced Resectable Gastric Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06030258Ifebemtinib (IN10018)Phase 1Small Cell Lung Cancer Extensive StageOncologyDec 2025
NCT05827796Ifebemtinib (IN10018)Phase 1Pancreatic CancerOncologyDec 2025
NCT05827796Erfonrilimab (KN046)Phase 1Pancreatic CancerOncologyDec 2025
NCT06654011Ifebemtinib (IN10018)Phase 2Cervical AdenocarcinomaOncologyMay 2026
NCT05551507Ifebemtinib (IN10018)Phase 1Platinum-resistant Ovarian CancerOncologyMay 2026
NCT05994131Ifebemtinib (IN10018)Phase 1NSCLCOncologyJul 2026
NCT06014528Ifebemtinib (IN10018)Phase 2Ovarian Cancer RecurrentOncologyDec 2026
NCT06099821Erfonrilimab (KN046)Phase 2Digestive System CancersOncologyDec 2026
NCT06023758Erfonrilimab (KN046)Phase 2HER2-positive Locally Advanced Resectable Gastric CancerOncologyDec 2026
NCT06166836Ifebemtinib (IN10018)Phase 1Solid TumorOncologyDec 2027
NCT06166836D-1553Phase 1Solid TumorOncologyDec 2027
NCT07652762Ifebemtinib (IN10018)Phase 1MeningiomaOncologyAug 2028
NCT07174908Ifebemtinib (IN10018)Phase 3Non-Small Cell Lung CancerOncologySep 2028
NCT07174908D-1553Phase 3Non-Small Cell Lung CancerOncologySep 2028
NCT07441174Ifebemtinib (IN10018)Phase 1Solid Tumor CancerOncologyFeb 2031
NCT07441174RNK08954Phase 1Solid Tumor CancerOncologyFeb 2031

Targets

PTK2 (1) CTLA4 (1) CD274 (1) KRAS (1)

Companies with the same targets

Revolution Medicines AstraZeneca Roche Bristol-Myers Squibb Pfizer Amgen TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Eli Lilly Verastem

Companies built like this

Genfleet Therapeutics (Shanghai) Verastem Day One Biopharmaceuticals Clarity Pharmaceuticals TYK Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.